Get the Stockscreener App
3.49
0.58%
0.02
After Hours:
3.49
Abcellera Biologics Inc stock is traded at $3.49, with a volume of 2.05M.
It is up +0.58% in the last 24 hours and up +12.58% over the past month.
AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.
See More
Previous Close:
$3.47
Open:
$3.52
24h Volume:
2.05M
Relative Volume:
0.51
Market Cap:
$1.06B
Revenue:
$75.13M
Net Income/Loss:
$-146.41M
P/E Ratio:
-7.1166
EPS:
-0.4904
Net Cash Flow:
$-174.43M
1W Performance:
+1.16%
1M Performance:
+12.58%
6M Performance:
-21.92%
1Y Performance:
+45.42%
1-Day Range:
$3.43
$3.655
1-Week Range:
$3.35
$3.67
52-Week Range:
$1.8906
$6.515
Abcellera Biologics Inc Stock (ABCL) Company Profile
Name
Abcellera Biologics Inc
Sector
Industry
Phone
(604) 559-9005
Address
150 W 4TH AVENUE, VANCOUVER
Compare ABCL vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABCL
Abcellera Biologics Inc
|
3.49 | 1.06B | 75.13M | -146.41M | -174.43M | -0.4904 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Abcellera Biologics Inc Stock (ABCL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jul-07-25 | Resumed | Leerink Partners | Outperform |
| Aug-20-24 | Downgrade | The Benchmark Company | Buy → Hold |
| Feb-22-24 | Upgrade | The Benchmark Company | Hold → Buy |
| Dec-05-23 | Initiated | KeyBanc Capital Markets | Overweight |
| Nov-06-23 | Downgrade | The Benchmark Company | Buy → Hold |
| Oct-13-23 | Resumed | Piper Sandler | Overweight |
| Feb-28-23 | Initiated | Cowen | Outperform |
| Dec-15-22 | Initiated | Goldman | Buy |
| Nov-16-22 | Initiated | Truist | Buy |
| Dec-21-21 | Initiated | The Benchmark Company | Buy |
| Nov-19-21 | Initiated | Piper Sandler | Overweight |
| Jan-05-21 | Initiated | BMO Capital Markets | Outperform |
| Jan-05-21 | Initiated | Berenberg | Buy |
| Jan-05-21 | Initiated | Credit Suisse | Outperform |
| Jan-05-21 | Initiated | SVB Leerink | Outperform |
| Jan-05-21 | Initiated | Stifel | Buy |
View All
Abcellera Biologics Inc Stock (ABCL) Latest News
AbCellera Biologics Inc. (NASDAQ:ABCL) Receives Average Rating of "Hold" from Analysts - MarketBeat
AbCellera Biologics Q1 2025 Earnings Preview - MSN
AbCellera Biologics Pivots to Pipeline as ABCL635 Phase II Hot Flash Data Nears, Exec Says - MarketBeat
AbCellera at TD Cowen Conference: Strategic Pipeline Insights By Investing.com - Investing.com Canada
DNB Asset Management AS Buys Shares of 656,208 AbCellera Biologics Inc. $ABCL - MarketBeat
Holdings Thermopylae Increases Stake in AbCellera Biologics Inc - GuruFocus
Thermopylae adds AbCellera (ABCL) shares in open-market buy - Stock Titan
AbCellera (ABCL) Is Up 18.8% After Pivoting To Clinical Stage And Filing Share Offering - simplywall.st
Thermopylae Holdings adds AbCellera (ABCL) shares in $3.27 open-market buy - Stock Titan
A Look At AbCellera Biologics (ABCL) Valuation After Narrower Losses And Pipeline Progress - simplywall.st
Decoding AbCellera Biologics Inc (ABCL): A Strategic SWOT Insigh - GuruFocus
Why AbCellera (ABCL) Is Up 11.5% After Narrowing Losses And Expanding ESOP Share Capacity – And What's Next - Yahoo Finance
AbCellera Biologics (ABCL) Pivots to Clinical Stage as 2025 Revenue Hits $75M - Insider Monkey
Abcellera Warns Growing Generative AI Use Raises Cybersecurity, Privacy, and Operational Risks - TipRanks
AbCellera Biologics Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
AbCellera Biologics (ABCL) Q4 Loss Narrows To US$0.03 EPS And Tests Bearish Narratives - simplywall.st
AbCellera (ABCL) Earnings Call: Liquidity, Risks, Catalysts - TipRanks
ABCL Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
AbCellera Reports Full Year 2025 Business Results - BioSpace
Why Axon Enterprise Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket - Benzinga
What Sparked AbCellera Biologics To Soar Over 9% After Hours - Bitget
AbCellera Biologics Inc (ABCL) Q4 2025 Earnings Call Highlights: Navigating Growth Amidst Challenges - GuruFocus
AbCellera Biologics Inc. (ABCL) reports Q4 loss, tops revenue estimates - MSN
AbCellera Biologics Inc. (ABCL) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
AbCellera Biologics Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:ABCL) 2026-02-24 - Seeking Alpha
AbCellera Biologics Q4 Earnings Call Highlights - MarketBeat
AbCellera Biologics Inc (NASDAQ:ABCL) Reports Narrower-Than-Expected Loss on Patent Settlement Windfall - ChartMill
AbCellera Biologics (NASDAQ:ABCL) Posts Earnings Results, Beats Estimates By $0.15 EPS - MarketBeat
Abcellera Biologics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
AbCellera (ABCL) Achieves Remarkable Revenue Growth in FY25 - GuruFocus
AbCellera Biologics Inc. SEC 10-K Report - TradingView
Abcellera Biologics earnings missed by $0.35, revenue topped estimates - Investing.com South Africa
AbCellera Biologics Q4 Earnings Report: What Investors Need to Know - Benzinga
AbCellera (NASDAQ: ABCL) 2025 results show revenue jump and strong liquidity - Stock Titan
AbCellera Biologics Experiences Revision in Stock Evaluation Amid Market Challenges - Markets Mojo
Earnings Scheduled For February 24, 2026 - Benzinga
AbCellera Biologics (ABCL) Set to Announce FY Earnings - GuruFocus
AbCellera Biologics FY 2025 earnings preview - MSN
AbCellera Biologics's Earnings Outlook - Benzinga
AbCellera Biologics Inc (ABCL) Misses Q4 2025 Earnings Estimates — EPS $-0.19 vs $-0.16 Expected - AlphaStreet
AbCellera Biologics Faces Stock Volatility Amid Strategic Decisions - timothysykes.com
AbCellera Biologics Inc (ABCL) down 23% since Q3 2025 results - MSN
Is AbCellera Biologics Inc affected by consumer sentimentJuly 2025 Recap & Real-Time Volume Spike Alerts - baoquankhu1.vn
AbCellera Biologics Inc. (ABCL) Investor Outlook: Potential Upside of 205% Amidst Biotech Innovations - DirectorsTalk Interviews
AbCellera Biologics Inc. (NASDAQ:ABCL) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
AbCellera Biologics (ABCL) Projected to Post Earnings on Tuesday - MarketBeat
Aug Mood: Is AbCellera Biologics Inc a potential multi baggerJuly 2025 Rallies & Expert-Curated Trade Recommendations - baoquankhu1.vn
AbCellera Biologics (NASDAQ:ABCL) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
AbCellera Biologics (NASDAQ:ABCL) Trading Up 8.3%Still a Buy? - MarketBeat
Abcellera Biologics Inc Stock (ABCL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.48%
1.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):